Implanet entered into a 6-year private label agreement with SeaSpine covering distribution of the Jazz® portfolio in the U.S.
SeaSpine will have exclusive rights to sell Jazz products under its own brand name, and the right to sell Jazz Cap®, a proprietary implant developed to treat degenerative spinal trauma, upon FDA clearance.
Implanet will continue to market the Jazz portfolio to its U.S. customers.
The agreement includes contractual annual minimum payments and gives SeaSpine exclusive access to co-developed products using Jazz technology.
“This partnership represents a major step forward for Implanet and is a testament to the tremendous clinical value of our proprietary Jazz technology,” said Ludovic Lastennet, Implanet’s Chief Executive Officer. “Establishing ourselves in the U.S. market has been our core strategy since 2016. SeaSpine’s sales and marketing team in the United States will accelerate our expansion in the world’s largest market. The partnership demonstrates our ability to develop disruptive technologies that meet market demand for new innovations. This fits our medium-term strategic development plan, which is predicated on rolling out our direct sales model in France, the U.S. and high-potential European markets (United Kingdom and Germany) while developing select strategic partnerships, such as that recently established with Kico Knee Innovation to distribute our Madison knee implant line in the United States and Australia.”
Implanet entered into a 6-year private label agreement with SeaSpine covering distribution of the Jazz® portfolio in the U.S.
SeaSpine will have exclusive rights to sell Jazz products under its own brand name, and the right to sell Jazz Cap®, a proprietary implant developed to treat degenerative spinal trauma, upon FDA clearance.
Implanet...
Implanet entered into a 6-year private label agreement with SeaSpine covering distribution of the Jazz® portfolio in the U.S.
SeaSpine will have exclusive rights to sell Jazz products under its own brand name, and the right to sell Jazz Cap®, a proprietary implant developed to treat degenerative spinal trauma, upon FDA clearance.
Implanet will continue to market the Jazz portfolio to its U.S. customers.
The agreement includes contractual annual minimum payments and gives SeaSpine exclusive access to co-developed products using Jazz technology.
“This partnership represents a major step forward for Implanet and is a testament to the tremendous clinical value of our proprietary Jazz technology,” said Ludovic Lastennet, Implanet’s Chief Executive Officer. “Establishing ourselves in the U.S. market has been our core strategy since 2016. SeaSpine’s sales and marketing team in the United States will accelerate our expansion in the world’s largest market. The partnership demonstrates our ability to develop disruptive technologies that meet market demand for new innovations. This fits our medium-term strategic development plan, which is predicated on rolling out our direct sales model in France, the U.S. and high-potential European markets (United Kingdom and Germany) while developing select strategic partnerships, such as that recently established with Kico Knee Innovation to distribute our Madison knee implant line in the United States and Australia.”
Copy to clipboard 
